QuiremScout™

Microspheres

Description

SELECT THE RIGHT PATIENTS, WITH CONFIDENCE

QuiremScout^TM: the first SIRT work-up product that uses the same technology as the therapeutic
microspheres, to optimize patient selection and advance treatment planning

Characteristics

QuiremScout^TM:

Contains the same microspheres as QuiremSpheres^TM(1)
has been shown to be safe in a study of 82 patients (2,3)
has been shown to be a better predictor for lung shunt and intrahepatic distribution than 99mTc-MAA (4,5)
has been shown to be more accurate at treatment planning than 99mTc-MAA, ensuring the right patients are identified for SIRT (6–8)

Preparation

Video instructions

Clinical evidence

The Holmium Platform

The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases

Maarten L. J. Smits et al. Eur. J. Nucl. Med. Mol. Imaging 2019

99mTc-MAA Overestimates the Absorbed Dose to the Lungs in Radioembolisation: A Quantitative Evaluation in Patients Treated with 166Ho Microspheres

Elschot, M. et al. Eur. J. Nucl. Med. Mol. Imaging 2014

See all clinical evidence

General specifications

Characteristics	99mTc-MAA	QuiremScout^TM	QuiremSpheres^TM
Particle Morphology
Material	MAA	PLLA	PLLA
Particle size (µm)	1 - 150	30 (15-60)	30 (15-60)
Number of particles (million)	0.2 - 1.2	3	30
Gamma energy	141 keV	81 keV	81 keV

Enlarge table

QuiremScout^TMis a product manufactured by Quirem Medical B.V and has CE-mark.

QuiremScout^TM is not available for sales in all countries. This information is provided only in respect to markets where the product is approved and cleared.

QuiremScout^TM is not FDA cleared in the US.

Item specifications

Item reference	Material description	Description
QS-S001	QuiremScout®	V-vial containing a small quantity of low-dose holmium-166 microspheres
QS-C001	Customer kit	Set of re-usable administration box and accessories for administration of QuiremSpheres^®
QS-D001	Delivery set	Set of sterile single-use tube lines for administration of QuiremSpheres^® (in a carton of 6 pieces)

Enlarge table

References

1 QuiremScout^TM 166Ho-Scout – Instruction for use
2 Braat et al. Eur Radiol 2018;28:920–28
3 Prince et al. J Nucl Med 2015;56:817–23
4. Elschot et al. Eur J Nucl Med Mol Imaging 2014;41:1965–75
5. Dassen et al. Presented at CIRSE 2018. Abstract available at: https://library.cirse.org/cirse2018/crs/the-predictive-value-of-theintrahepatic-
distribution-of-99mtc-macroaggregated-albumin-and-holmium-166-scout-dose-prior-to-holmium-166-radioembolization
6. Grosche-Schlee et al. QuiremScout^TM case study. Available at: https://www.terumo-europe.com/en-emea/clinical-program/Clinical%20
Data/E_Clinical_Case_Studies_QuiremScout_LR.PDF#search=SIRT%20case%20study
7. Smits et al. Eur J Nucl Med Mol Imaging 2020;47:798–806
8. Chiesa and Maccauro. Eur J Nucl Med Mol Imaging 2020;47:744–47

Do you need more info about this product?

Our sales representatives are here for you.

Send us a message

First name *

Last name *

Function

Company *

Country *

E-mail address *

Question *

I have read and accept Terumo Privacy And Cookies Policy and the Terms Of Use*

I wish to receive information and marketing updates from Terumo.

* mandatory fields

Thank you for contacting us!

We typically respond within 2 business days and will come back to you as soon as possible.

Didn't find your product?

Consult our products in our Product Index

Are you a healthcare professional?

This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public

For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.